Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 17:20:254.
doi: 10.1186/s12935-020-01342-4. eCollection 2020.

MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma

Babak Otoukesh  1   2 , Mehdi Abbasi  3 , Habib-O-Lah Gorgani  2 , Hossein Farahini  2 , Mehdi Moghtadaei  2 , Bahram Boddouhi  2 , Peyman Kaghazian  4 , Shayan Hosseinzadeh  5 , Atefe Alaee  6
Affiliations
Review

MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma

Babak Otoukesh et al. Cancer Cell Int. .

Abstract

MicroRNAs (miRNAs) involved in key signaling pathways and aggressive phenotypes of osteosarcoma (OS) was discussed, including PI3K/AKT/MTOR, MTOR AND RAF-1 signaling, tumor suppressor P53- linked miRNAs, NOTCH- related miRNAs, miRNA -15/16 cluster, apoptosis related miRNAs, invasion-metastasis-related miRNAs, and 14Q32-associated miRNAs cluster. Herrin, we discussed insights into the targeted therapies including miRNAs (i.e., tumor-suppressive miRNAs and oncomiRNAs). Using bioinformatics tools, the interaction network of all OS-associated miRNAs and their targets was also depicted.

Keywords: MicroRNAs; Osteosarcoma; Targets; Therapy.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Possible ways to release circulating miRNAs; 3 pathways including extracellular vesicles, RNA-binding proteins and/or transfer through cell gap junction are involved. In addition, the topology of the network was analyzed based on degree metrics in order to find the most important nodes. According to the findings, 5 nodes with large degrees in our large network (i.e., > 9, see green nodes) including BCL2, VEGFA, CCND1, PTEN and MET were identified as potential hub nodes, (Additional file 1, and Fig. 2)
Fig. 2
Fig. 2
the sub-network showed the potential hub gene nodes (nodes with over 9 in degrees): BCL2 (13), VEGFA (12), CCND1 (11), PTEN (11), MET (10) and miRNAs that regulated them
Fig. 3
Fig. 3
Limitations and challenges for miRNA delivery into cancer in clinical trials
See this image and copyright information in PMC

References

    1. Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):E1310. - PMC - PubMed
    1. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402. - PMC - PubMed
    1. Van den Brande S, Gijbels M, Wynant N, Santos D, Mingels L, Gansemans Y, et al. The presence of extracellular microRNAs in the media of cultured Drosophila cells. Sci Rep. 2018;8(1):17312. - PMC - PubMed
    1. Max KEA, Bertram K, Akat KM, Bogardus KA, Li J, Morozov P, et al. Human plasma and serum extracellular small RNA reference profiles and their clinical utility. Proc Natl Acad Sci USA. 2018;115(23):E5334–E5343. - PMC - PubMed
    1. Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and potential targets in osteosarcoma: review. Front Pediatr. 2015;3:69. - PMC - PubMed